NDM9357 - Member Debates

Tabled on 11/11/2026 | For debate on 16/12/2026

To propose that the Senedd:

1. Notes the:

a) campaign for Owain’s Law, named after Owain James, who passed away from a brain tumour in 2024; and

b) work of the late Dr Hefin David MS, who led a Member Legislative Proposal debate on Owain’s Law in 2025.

2. Welcomes the:

a) Welsh Government’s commitment to strengthen arrangements around patient consent for brain tumour surgery and the retention and storage of brain tumour tissue, including freezing where clinically appropriate; and

b) contribution of patients, families, clinicians and campaigners to raising awareness of the importance of clear information and informed discussion around the handling and retention of brain tumour tissue.

3. Believes that:

a) patients and their families should receive clear and consistent information about the handling, retention and potential uses of brain tumour tissue removed during surgery; and

b) where clinically appropriate, opportunities should be maximised for brain tumour tissue to support diagnosis, molecular testing, treatment planning, research and potential future clinical trial opportunities.

4. Calls on the Welsh Government to:

a) consider the most effective and deliverable means, including whether national guidance is required, to strengthen arrangements around patient consent for brain tumour surgery and the retention and storage of brain tumour tissue, including freezing where clinically appropriate;

b) work with patients and families, clinicians, NHS organisations, pathology services, specialist services supporting Welsh patients, including those outside Wales, professional bodies and regulators in developing these measures;

c) strengthen arrangements to ensure patients and families receive consistent, relevant and sufficient information before surgery about what may happen to tissue removed during surgery, and how it may be retained and used;

d) strengthen the consistency with which information and consent discussions are recorded and followed up; and

e) ensure that any new arrangements maximise the appropriate retention and use of brain tumour tissue while prioritising accurate and timely diagnosis, and protecting patient safety, clinical judgement and established specialist care pathways.

Supporters